(Circulation. 1999;99:2942-2950.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo (T.N., K.I., H.O., H.I., H.H., M.A., T.M., F.N., J.S., M.O.), and the Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba (S.S., Y.K., Y.O.), Ibaraki, Japan.
Correspondence to T. Nakajima, MD, Second Department of Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
BackgroundIt has been suggested that intracellular Ca2+ overload in cardiac myocytes leads to the development of diabetic cardiomyopathy. Troglitazone, an insulin-sensitizing agent, is a promising therapeutic agent for diabetes and has been shown to prevent diabetes-induced myocardial changes. To elucidate the underlying mechanism of troglitazone action on cardiac myocytes, the effects of troglitazone on voltage-dependent Ca2+ currents were examined and compared with classic Ca2+ antagonists (verapamil and nifedipine).
Methods and ResultsWhole-cell voltage-clamp techniques were applied in single guinea pig atrial myocytes. Under control conditions with CsCl internal solution, the voltage-dependent Ca2+ currents consisted of both T-type (ICa,T) and L-type (ICa,L) Ca2+ currents. Troglitazone effectively reduced the amplitude of ICa,L in a concentration-dependent manner. Troglitazone also suppressed ICa,T, but the effect of troglitazone on ICa,T was less potent than that on ICa,L. The current-voltage relationships for ICa,L and the reversal potential for ICa,L were not altered by troglitazone. The half-maximal inhibitory concentration of troglitazone on ICa,L measured at a holding potential of -40 mV was 6.3 µmol/L, and 30 µmol/L troglitazone almost completely inhibited ICa,L. Troglitazone 10 µmol/L did not affect the time courses for inactivation of ICa,L and inhibited ICa,L mainly in a use-independent fashion, without shifting the voltage-dependency of inactivation. This effect was different from those of verapamil and nifedipine. Troglitazone also reduced isoproterenol- or cAMP-enhanced ICa,L.
ConclusionsThese results demonstrate that troglitazone inhibits voltage-dependent Ca2+ currents (T-type and L-type) and then antagonizes the effects of isoproterenol in cardiac myocytes, thus possibly playing a role in preventing diabetes-induced intracellular Ca2+ overload and subsequent myocardial changes.
Key Words: troglitazone myocytes calcium isoproterenol diabetes cardiomyopathy
This article has been cited by other articles:
![]() |
T.-M. Lee and T.-F. Chou Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1650 - H1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Terasawa, T. Nakajima, H. Iida, K. Iwasawa, H. Oonuma, T. Jo, T. Morita, F. Nakamura, Y. Fujimori, T. Toyo-oka, et al. Nonselective Cation Currents Regulate Membrane Potential of Rabbit Coronary Arterial Cell: Modulation by Lysophosphatidylcholine Circulation, December 10, 2002; 106(24): 3111 - 3119. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yoshida SIMPLE TECHNIQUES SUITABLE FOR STUDENT USE TO RECORD ACTION POTENTIALS FROM THE FROG HEART Advan Physiol Educ, September 1, 2001; 25(3): 176 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
Li Yao, K. Mizushige, T. Noma, K. Murakami, K. Ohmori, and H. Matsuo Improvement of Left Ventricular Diastolic Dynamics in Prediabetic Stage of A Type II Diabetic Rat Model After Troglitazone Treatment Angiology, January 1, 2001; 52(1): 53 - 57. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |